Literature DB >> 22173044

Secretory phospholipase A2-mediated depletion of phosphatidylglycerol in early acute respiratory distress syndrome.

Michael C Seeds1, Bonnie L Grier, Bruce N Suckling, Anca M Safta, David L Long, B Moseley Waite, Peter E Morris, R Duncan Hite.   

Abstract

INTRODUCTION: Secretory phospholipases A2 (sPLA2) hydrolyze phospholipids in cell membranes and extracellular structures such as pulmonary surfactant. This study tests the hypothesis that sPLA2 are elevated in human lungs during acute respiratory distress syndrome (ARDS) and that sPLA2 levels are associated with surfactant injury by hydrolysis of surfactant phospholipids.
METHODS: Bronchoalveolar lavage (BAL) fluid was obtained from 18 patients with early ARDS (<72 hours) and compared with samples from 10 healthy volunteers. Secreted phospholipase A2 levels were measured (enzyme activity and enzyme immunoassay) in conjunction with ARDS subjects' surfactant abnormalities including surfactant phospholipid composition, large and small aggregates distribution and surface tension function.
RESULTS: BAL sPLA2 enzyme activity was markedly elevated in ARDS samples relative to healthy subjects when measured by ex vivo hydrolysis of both phosphatidylglycerol (PG) and phosphatidylcholine (PC). Enzyme immunoassay identified increased PLA2G2A protein in the ARDS BAL fluid, which was strongly correlated with the sPLA2 enzyme activity against PG. Of particular interest, the authors demonstrated an average depletion of 69% of the PG in the ARDS sample large aggregates relative to the normal controls. Furthermore, the sPLA2 enzyme activity against PG and PC ex vivo correlated with the BAL recovery of in vivo PG and PC, respectively, and also correlated with the altered distribution of the large and small surfactant aggregates.
CONCLUSIONS: These results support the hypothesis that sPLA2-mediated hydrolysis of surfactant phospholipid, especially PG by PLA2G2A, contributes to surfactant injury during early ARDS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22173044      PMCID: PMC3307942          DOI: 10.1097/MAJ.0b013e318239c96c

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  50 in total

1.  Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis.

Authors:  Norbert Degousee; Farideh Ghomashchi; Eva Stefanski; Alan Singer; Brian P Smart; Niels Borregaard; Reinhardt Reithmeier; Thomas F Lindsay; Cornelia Lichtenberger; Walter Reinisch; Gerard Lambeau; Jonathan Arm; Jay Tischfield; Michael H Gelb; Barry B Rubin
Journal:  J Biol Chem       Date:  2001-12-06       Impact factor: 5.157

2.  Cytokine balance in the lungs of patients with acute respiratory distress syndrome.

Authors:  W Y Park; R B Goodman; K P Steinberg; J T Ruzinski; F Radella; D R Park; J Pugin; S J Skerrett; L D Hudson; T R Martin
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

3.  A comparison of the molecular species compositions of mammalian lung surfactant phospholipids.

Authors:  A D Postle; E L Heeley; D C Wilton
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2001-05       Impact factor: 2.320

4.  Sera of patients suffering from inflammatory diseases contain group IIA but not group V phospholipase A(2).

Authors:  A J Aarsman; F W Neys; H A van der Helm; F A Kuypers; H van den Bosch
Journal:  Biochim Biophys Acta       Date:  2000-10-18

5.  SP-B refining of pulmonary surfactant phospholipid films.

Authors:  K Nag; J G Munro; K Inchley; S Schürch; N O Petersen; F Possmayer
Journal:  Am J Physiol       Date:  1999-12

6.  Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-acquired pneumonia.

Authors:  Yao-Ling Lee; Wei Chen; Ling-Yun Chen; Chia-Hung Chen; Yu-Chao Lin; Shinn-Jye Liang; Chuen-Ming Shih
Journal:  J Crit Care       Date:  2009-07-09       Impact factor: 3.425

Review 7.  Pulmonary surfactant for neonatal respiratory disorders.

Authors:  Jeffrey D Merrill; Roberta A Ballard
Journal:  Curr Opin Pediatr       Date:  2003-04       Impact factor: 2.856

8.  Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2.

Authors:  Alan G Singer; Farideh Ghomashchi; Catherine Le Calvez; James Bollinger; Sofiane Bezzine; Morgane Rouault; Martin Sadilek; Eric Nguyen; Michel Lazdunski; Gerard Lambeau; Michael H Gelb
Journal:  J Biol Chem       Date:  2002-09-30       Impact factor: 5.157

9.  Lipid compositional analysis of pulmonary surfactant monolayers and monolayer-associated reservoirs.

Authors:  Shou-Hwa Yu; Fred Possmayer
Journal:  J Lipid Res       Date:  2003-01-01       Impact factor: 5.922

Review 10.  Surfactant alteration and replacement in acute respiratory distress syndrome.

Authors:  A Günther; C Ruppert; R Schmidt; P Markart; F Grimminger; D Walmrath; W Seeger
Journal:  Respir Res       Date:  2001-10-12
View more
  16 in total

1.  IL-6 trans-signaling increases expression of airways disease genes in airway smooth muscle.

Authors:  Mac B Robinson; Deepak A Deshpande; Jeffery Chou; Wei Cui; Shelly Smith; Carl Langefeld; Annette T Hastie; Eugene R Bleecker; Gregory A Hawkins
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-05-22       Impact factor: 5.464

2.  Tracheal acid or surfactant instillation raises alveolar surface tension.

Authors:  Tam L Nguyen; Carrie E Perlman
Journal:  J Appl Physiol (1985)       Date:  2018-05-17

3.  Surfactant protein B inhibits secretory phospholipase A2 hydrolysis of surfactant phospholipids.

Authors:  R Duncan Hite; Bonnie L Grier; B Moseley Waite; Ruud A Veldhuizen; Fred Possmayer; Li-Juan Yao; Michael C Seeds
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-10-28       Impact factor: 5.464

4.  Plasma lipid profile: a predictive marker of disease severity among COVID-19 patients-an opportunity for low-income countries.

Authors:  Yasser O Mosaad; Mohamed A Baraka; Ahmed E Abou Warda; Hayam Ateyya; Mohammed A Hussein; Sayed Gaber
Journal:  Drugs Ther Perspect       Date:  2022-06-27

5.  Sulforhodamine B and exogenous surfactant effects on alveolar surface tension under acute respiratory distress syndrome conditions.

Authors:  Tam L Nguyen; Carrie E Perlman
Journal:  J Appl Physiol (1985)       Date:  2020-09-24

6.  Role of inositol to improve surfactant functions and reduce IL-6 levels: A potential adjuvant strategy for SARS-CoV-2 pneumonia?

Authors:  Antonio Simone Laganà; Vittorio Unfer; Simone Garzon; Mariano Bizzarri
Journal:  Med Hypotheses       Date:  2020-09-09       Impact factor: 1.538

7.  Lung Surfactant Accelerates Skin Wound Healing: A Translational Study with a Randomized Clinical Phase I Study.

Authors:  Ursula Mirastschijski; Igor Schwab; Vincent Coger; Ulrich Zier; Carmela Rianna; Wei He; Kathrin Maedler; Sørge Kelm; Arlo Radtke; Gazanfer Belge; Patrick Lindner; Frank Stahl; Martin Scharpenberg; Lukas Lasota; Jürgen Timm
Journal:  Sci Rep       Date:  2020-02-13       Impact factor: 4.379

8.  Decreased surfactant lipids correlate with lung function in chronic obstructive pulmonary disease (COPD).

Authors:  Christina W Agudelo; Britta K Kumley; Estela Area-Gomez; Yimeng Xu; Abdoulaye J Dabo; Patrick Geraghty; Michael Campos; Robert Foronjy; Itsaso Garcia-Arcos
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

9.  Synthetic surfactant with a recombinant surfactant protein C analogue improves lung function and attenuates inflammation in a model of acute respiratory distress syndrome in adult rabbits.

Authors:  J Zebialowicz Ahlström; F Massaro; P Mikolka; R Feinstein; G Perchiazzi; O Basabe-Burgos; T Curstedt; A Larsson; J Johansson; A Rising
Journal:  Respir Res       Date:  2019-11-06

10.  Intravenous sulforhodamine B reduces alveolar surface tension, improves oxygenation, and reduces ventilation injury in a respiratory distress model.

Authors:  You Wu; Tam L Nguyen; Carrie E Perlman
Journal:  J Appl Physiol (1985)       Date:  2020-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.